Ajuts a la recerca

IMI -Discovery and validation of novel endpoints in dry age-related macular degeneration and diabetic retinopathy

Organisme

EU- Innovative Medicines Initiative

Objecte

Specific challenge

Diseases of the retina are among the leading causes of blindness worldwide. Substantial progress has been made in the treatment of neovascular age-related macular degeneration (neovascular AMD) and diabetic macular edema (DME). However, for other common retinal conditions such as the dry form of AMD (dry AMD) or diabetic retinopathy (DR) treatment options remain limited. One major development hurdle is the lack of suitable, patient-relevant study endpoints with clinical relevance for both early exploratory and pivotal trials. Moreover, there are gaps in the understanding on how preclinical findings translate into outcomes.
 

Termini oficial

Deadline for submission: 12 November 2014 – 17:00 CET

Termini IISPV

Declaration of interest: IISPV's deadline: August 31, 2014 (europa@iispv.cat) Full proposal: IISPV's deadline: October 29, 2014

Pujar